IND 11 - Redefining excellence in contrast-enhanced MRI: the benefits of gadopiclenol (Vueway)

Gadopiclenol (Vueway) is a new, highly stable gadolinium-based contrast agent (GBCA) for MRI whose r1 relaxivity is 2-3 times higher than the r1 relaxivity values of other currently available GBCAs. It is approved in the USA and Europe for CNS and body indications at a dose of 0.05 mmol/kg bodyweight which is half that of other purely extracellular fluid GBCAs. This means that patients are exposed to half the amount of gadolinium without loss of diagnostic information, and that half the amount of gadolinium enters the environment. This symposium will focus on the safety of gadopiclenol, on its role in improving environmental sustainability and on the clinical benefits of 0.05 mmol/kg gadopiclenol specifically in MRI of the CNS and abdomen.